ACCESSWIRE

Meta Materials Inc.

Share
META Appoints Darren Ihmels as Vice President of Business Development Ophthalmics

HALIFAX, NS / ACCESSWIRE / July 23, 2021 / Meta Materials Inc. (the "Company" or "META®") (NASDAQ:MMAT) a developer of high-performance functional materials and nanocomposites, today announced it has appointed Mr. Darren Ihmels as Vice President Business Development Ophthalmics. Mr. Ihmels brings over 30 years of experience in opthalmic products, sales, manufacturing, equipment, and services for prescription lenses and smart augmented reality (AR) applications. He will be focused on growing META's ARfusion™ technology, which combines precision cast lens fabrication tools and functional metamaterials and volume holograms, to provide META's AR wearable developers with a platform for seamlessly integrating smart technologies into thin lightweight prescription glasses.

"To develop a commercially successful augmented reality eyewear business, it is necessary to elegantly combine the attributes of fashionable, lightweight and comfortable prescription eyewear with embedded smart technologies and displays," said George Palikaras, President and CEO of META. "We are fortunate to have someone of Darren's breadth of experience join our team as we commercialize the ARfusion™ system."

Mr. Ihmels joins META from Google. Previously, from 2016 to 2020, he was Director, Opthalmic Lens Manufacturing for North, Inc. From 2009 to 2015, he was a Vice President in several sales roles and VP Manufacturing for FYidoctors, Canada's largest eyecare provider. From 2001 to 2009, Ihmels was National Service Manager for Visionix, a part of the Luneau Technology Group, a provider of equipment for vision correction. From 1995 to 2001, Ihmels was National Manufacturing Director for Pearle Vision in Canada. He began his career with LensCrafters in 1989, where he rose to the position of Lab Manager.

"I am excited to join a fast-paced and highly innovative environment like Meta Materials. I look forward of applying my 30 years of experience in the ophthalmics industry, including some pioneering work in the last decade in smart glasses for augmented reality applications, to help META expand its business into this key high growth market," said Darren Ihmels.

For more details about ARfusion™ and META's ophthalmics roadmap, please refer to our latest blog post.

About Meta Materials Inc.

META® delivers previously unachievable performance, across a range of applications, by inventing, designing, developing, and manufacturing sustainable, highly functional materials. Our extensive technology platform enables leading global brands to deliver breakthrough products to their customers in consumer electronics, 5G communications, health and wellness, aerospace, automotive, and clean energy. Our achievements have been widely recognized, including being named a Global Cleantech 100 company. Learn more at www.metamaterial.com.

Forward Looking Information

This press release includes forward-looking information or statements within the meaning of Canadian securities laws and within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, regarding the Company and its business, which may include, but are not limited to, statements with respect to the business strategies, product development and operational activities of the Company. Often but not always, forward-looking information can be identified by the use of words such as "potential," "predicts," "projects," "seeks," "plans," "expect", "intends", "anticipated", "believes" or variations (including negative variations) of such words and phrases, or statements that certain actions, events or results "may", "could", "should," "would" or "will" be taken, occur or be achieved. Such statements are based on the current expectations and views of future events of the management of the Company and are based on assumptions and subject to risks and uncertainties. Although the management of the Company believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting the Company, including risks related to developing products for the augmented reality eyewear market, the management and potential divestiture of the assets in the Company's oil and gas business, the potential benefits of the Company being publicly listed on the Nasdaq Capital Market, the potential benefits of the transaction with Torchlight Energy Resources Inc. to the Company's stockholders, the research and development projects of the Company, the market potential of the Company's products, the investment priorities and manufacturing plans of the Company, the scalability of the Company's production ability, the technology industry, market strategic and operational activities, and management's ability to manage and to operate the business. More details about these and other risks that may impact the Company's businesses are described under the heading "Risk Factors" in the Company's Form 8-K filed with the SEC on July 2, 2021, in the Company's Form 10-Q filed with the SEC on May 14, 2021, in the Company's Form 10-K filed with the SEC on March 18, 2021, and in subsequent filings made by Meta Materials with the SEC, which are available on SEC's website at www.sec.gov. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward looking statement, whether as a result of new information, future events, or otherwise, except to the extent required by law.

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

Contact

Mark Komonoski
Senior Vice President
Integrous Communications
Phone: 1-877-255-8483
Email: ir@metamaterial.com

Media inquiries:

media@metamaterial.com

SOURCE: Meta Materials Inc.



View source version on accesswire.com:
https://www.accesswire.com/656794/META-Appoints-Darren-Ihmels-as-Vice-President-of-Business-Development-Ophthalmics

To view this piece of content from www.accesswire.com, please give your consent at the top of this page.

About ACCESSWIRE

DK

Subscribe to releases from ACCESSWIRE

Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESSWIRE

Opti Digital Breaks Down the Biggest AdTech Trends in 202518.10.2024 03:40:00 CEST | Press release

As the ad tech landscape evolves, 2025 promises to be a pivotal year for digital advertising, with key trends already emerging. BARCELONA, SPAIN / ACCESSWIRE / October 18, 2024 / Magali Quentel-Reme, CEO of Opti Digital; Mohsin Pervez, Senior Director of Platform Solutions and Operations, EMEA at PubMatic; and Langdon Miller, Director of Programmatic at Brainly, share their insights on the future of the AdTech landscape and the key trends set to shape programmatic in 2025. Addressability Solution With over 50% of third-party cookies already phased out and Google's pivotal July 2024announcement granting users control over cookie settings, the need for effective alternatives is more critical than ever. Langdon Miller, Director of Programmatic at Brainly, explains that "the integration of probabilistic and deterministic IDs, first-party data, contextual segmentation, and bid decoration has led to sustained performance and increased yield." This is echoed on the buy side, with a growing re

Participation in the Multilateral System Remains High as Performance Drops, New Index Finds17.10.2024 13:00:00 CEST | Press release

The Multilateralism Index 2024 reveals a contradiction: while participation in the multilateral system has largely held steady or even increased, its effectiveness in addressing global challenges has declined. WASHINGTON, DC / ACCESSWIRE / October 17, 2024 / Today marks the launch of the second edition of the Multilateralism Index from the International Peace Institute (IPI) and the Institute for Economics & Peace (IEP). The Index reveals that states remain engaged in the global multilateral system even as it increasingly struggles to address the crises it faces. Multilateralism Index 2024 Report An image of the front cover of the Multilateralism Index 2024 Report Key results The performance of the multilateral system declined across all five domains examined. Peace and security showed the steepest deterioration in performance, with the number of armed conflicts rising from 39 in 2013 to 55 in 2022. Climate action and human rights also saw significant declines in performance, despite i

Athos Announces Positive Topline Phase 1 Data for its AI-Generated, Novel, Oral G9A Inhibitor ATH-063, Demonstrating Selective Expansion and Activation of Potent Anti-Inflammatory Regulatory T Cells16.10.2024 09:00:00 CEST | Press release

ATH-063 significantly increased the number of circulating regulatory T cells (Tregs) across all doses and demonstrated enrichment in six well-described genes related to induced Treg anti-inflammatory activities No serious adverse effects or dose limiting toxicities were observed at any dose level, and ATH-063 demonstrated favorable pharmacokinetics (PK) The data provides clinical verification for Athos' Proprietary AI2 (Artificial Intelligence for Autoimmune drug development) computational software platform which generated ATH-063 LOS ANGELES, CA / ACCESSWIRE / October 16, 2024 / Athos Therapeutics, Inc. ("Athos"), a clinical stage biotechnology company pioneering the development of precision small molecule therapeutics for patients with immune-mediated diseases, today announced topline results for the company's Phase 1 clinical trial of ATH-063, an investigational oral small molecule G9A inhibitor and the company's lead asset in development for the treatment of inflammatory bowel dise

Probabl (The Official Operator of the Scikit-Learn Brand) Selects Kryterion to Provide Certification to Millions of Data Scientists in Machine Learning16.10.2024 08:40:00 CEST | Press release

HARROW, UK / ACCESSWIRE / October 16, 2024 / Kryterion, a leader in certification test development and delivery solutions, was selected by Probabl, the official operator of the scikit-learn brand, to deliver the first-ever official certification programme targeting millions of data scientists. The scikit-learn software library has registered over 1.5 billion downloads and is the gold standard for open-source machine learning in the Python ecosystem, underpinning over 1 million global projects. Kryterion's proven track record as a secure, scalable certification platform makes it the ideal partner for delivering this groundbreaking programme. Kryterion & Probabl Probabl and Kryterion will support the global data science community by offering the first globally recognised certification in scikit-learn. As the official operator of the scikit-learn brand, Probabl is spearheading the initiative to provide structured certification across three key tiers: associate, professional, and expert. T

Moolec Has Received USDA Approval for the First Genetically Modified Pea in History16.10.2024 06:00:00 CEST | Press release

LUXEMBOURG / ACCESSWIRE / October 16, 2024 / Moolec Science SA (NASDAQ:MLEC) ("the Company"), a leader in Molecular Farming technology, announced today that the U.S. Department of Agriculture's ("USDA") Animal and Plant Health Inspection Service ("APHIS") has completed its Regulatory Status Review ("RSR") for the Company's genetically engineered ("GE") peas which produce iron through bovine meat proteins. This is the third regulatory clearance from USDA-APHIS achieved by Moolec in an 18-month window, alongside its genetically engineered safflower and soybean for GLASO™ and Piggy Sooy™ products, respectively. Access the official USDA-APHIS publication here. "With USDA approval for our GE pea, Moolec has now secured regulatory clearance for all of our key crops in the US: safflower, soybean, and pea," said Gastón Paladini, CEO and Co-Founder of Moolec. "We are proud to be the only Molecular Farming company with three US regulatory approvals and a major commercial contract. This milestone

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye